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Acute hepatitis B in a healthcare worker: A case report
of genuine vaccination failureq
Hein J. Boot1,*, Laurens A. van der Waaij2, Jurjen Schirm3, Cees G.M. Kallenberg4,
Jim van Steenbergen1, Bert Wolters5
1Centre for Infectious Disease Control, National institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands
2Department of Gastroenterology, Martini Hospital, Groningen, The Netherlands
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5Municipal Health Service, Groningen, The NetherlandsBackground: Individuals who reach the antibody threshold level of 10 IU/ l against the surface protein of the hepatitis B
virus (HBV) after completion of a series of hepatitis B vaccination are considered to be long-term protected against a clin-
ically manifest HBV infection.
Case report:Here we describe an acute hepatitis B infection in a patient who received ﬁve hepatitis B vaccinations.
Although his initial response to vaccination was moderate, he ﬁnally reached an excellent hepatitis B surface antibody level
(anti-HBs) titres of more than 1000 IU/ l in response to a booster vaccination with a recombinant DNA vaccine. Never-
theless, he developed full-blown acute hepatitis due to an HBV infection 14 years after this booster vaccination. A DNA
analysis of the surface protein encoding region followed by phylogenetic analysis showed that our patient was infected with
a normal HBV strain that is circulating among men who have sex with men. To our knowledge, this is the ﬁrst report of a
genuine hepatitis B vaccination failure in someone who acquired a high anti-HBs level in response to a recombinant DNA
hepatitis B vaccine.
Conclusion:Healthcare workers whose response to the initial hepatitis B vaccination is moderate might be vulnerable to
hepatitis B virus infection.
 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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derived and recombinant DNA hepatitis B (HB) vac-
cines are very eﬀective at the population level [1,2].
For individuals, the internationally accepted guideline
for long-term protection against HBV infection is a
level of anti-HBs antibodies of at least 10 IU/l at 1–
3 months post-vaccination [3–5]. However, a relatively
large proportion of HB vaccine recipients – up to
10% of adult vaccinees – respond low (serum antibody
level <10 IU/l) or not at all (<1 IU/l) [2]. Low and
non-response depend on many factors such as age,
genetic constitution, obesity, smoking, etc. [6–8].Published by Elsevier B.V. All rights reserved.
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for antibodies to the HB core (HBc) antigen – have
been reported both for children and adults with proven
adequate HB vaccine responses. However, such break-
through infections are considered clinically irrelevant,
as they are without symptoms and do not result in
chronic HBV infections [2].
Hepatitis B virus can establish sub-clinical chronic
infection and is highly transmissible by blood–blood
contacts in non-vaccinated individuals. These proper-
ties, in combination with vaccination failures, might
lead to unnoticed transmission, especially in a health-
care setting [9]. In developed countries, low and non-
responders are oﬀered revaccination, which results in
the seroconversion of most low responders [4], but
about half of the non-responders do not develop HB
surface (HBs) antibody levels even after repeated vacci-
nations [10]. Individuals who initially respond well to
HB vaccination, but do not have detectable anti-HBs
titres at the time of HBV exposure are considered to
be protected due to an anamnestic immune response
to exposure to HBV. Because HB vaccines have only
been available since the early 1980s, data about long-
term protection are limited. Here we report an acute
HBV infection in a 50-year-old healthcare worker who
received ﬁve HB-vaccinations in the last 22 years and,
based on his post-vaccination anti-HBs titres, was con-
sidered to be adequately protected against a clinical
HBV infection.Table 1
History of hepatitis B vaccination, hepatitis B vaccine response and hepatitis-B
Year Date Vaccine Anti-HBs1 Relevant st
1985 24-07-85 HBVax (plasma)
1985 20-08-85 HBVax (plasma)
1986 25-02-86 HBVax (plasma)
1986 06-08-86 Positive (SRU = 10)
1987 20-05-87 Negative (SRU = 0)
1987 26-05-87 HBVax (plasma)
1987 26-06-87 Positive (SRU = 11)
1993 17-08-93 HBVax (rec. DNA)
1993 19-10-93 Positive (>1000 IU/l)
1994 07-03-94 Positive (>1000 IU/l) Negative: H
20042 04-10-04 Negative (0 IU/l) Negative: H
2007 19-03-07 Onset of cli
2007 29-03-07 Negative (0 IU/l) Positive: HB
Negative: H
ALAT = 35
2007 04-06-07 Negative (0.4 IU/l) Positive: HB
2007 26-10-07 Positive (10.2 IU/l) Positive: an
Negative: H
2007 09-11-07 Positive (12.3 IU/l) Negative: a
1 Anti-HBs values are given as sample ratio units (SRU) or International
2 Result of retrospective analysis of stored serum.
3 HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; Ant
against the hepatitis B core antigen; Anti-HIV, antibodies against human im
G; HAV, hepatitis A virus; EBV, Epstein-Barr virus; CMV, Cytolomegaviru2. Case report
A 50-year-old homosexual Caucasian man, who
was born and raised in the Netherlands and who
had worked in a hospital setting for more than
25 years, developed classical symptoms of acute hepa-
titis. At the time when his general practitioner referred
him to the hospital, he had nausea for 10 days accom-
panied by anorexia and mild upper-abdominal pain.
He had developed jaundice with yellow-brown faeces
and dark urine 5 days before referral. He had no pru-
ritis. His daily alcohol consumption had been moder-
ate in the preceding years. He had used omeprazole
and atenolol for more than 5 years. At physical exam-
ination, he was jaundiced and had a tender liver, but
it was not enlarged, and no signs of chronic liver dis-
ease or encephalopathy were present. At admission,
aminotransferase activities were 3510 U/l for alanine
aminotransferase (ALAT; normal <40), 2243 U/l for
aspartate aminotransferase (ASAT; normal <40), and
a total bilirubin level of 128 lmol/l (normal <18).
Six weeks later, the liver transaminases were normal
and the patient was asymptomatic. No signs of liver
failure developed during the course of the disease.
At admission, serologic testing was positive for HB
surface antigen (HBsAg), HB e antigen (HBeAg) and
anti-HBc (both IgM and IgG), while other serologic
tests were negative (Table 1). Acute infection with
HBV was subsequently diagnosed.-virus-related disease.
atus3
BsAg, anti-HBe and anti-HBc
BsAg, anti-HBc, anti-HIV
nical symptoms
sAg (>250 IU/ml), HBeAg, anti-HBc (total and IgM), and HBV DNA
AV (IgM), EBV (IgM and IgG) and CMV (IgM and IgG)
10 IU/l; Bilirubin = 205 lmol/l
sAg (58 IU/ml), HBeAg and anti-HBc (total and IgM)
ti-HBe & anti-HBc (total and IgM)
BsAg, HBeAg and HBV DNA
nti-HIV
Units per litre (IU/l).
i-HBe, antibodies against hepatitis B e antigen; Anti-HBc, antibodies
munodeﬁciency virus; IgM, immunoglobulin M; IgG, immunoglubulin
s; ALAT, alanine aminotransferase.
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Fig. 1. History of hepatitis B vaccination and relevant serologic analysis prior to the onset of acute hepatitis B in 2007.
428 H.J. Boot et al. / Journal of Hepatology 50 (2009) 426–431The patient received his initial HB-vaccinations (2
primary and 1 booster) with plasma-derived vaccine in
1985–1986 (see Fig. 1 for a chronologic overview and
Table 1 for details). A moderate immunization response
was recorded 5 months after the booster of the initial
vaccination series. However, 10 months later serologic
evaluation showed a complete lack of anti-HBs. A sub-
sequent booster was given, again resulting in a moderate
immunization response. Six years later, he received a
single booster vaccination with a recombinant HB vac-
cine, resulting in a high level of anti-HBs (>1000 IU/l).
Six months later he still had a very high level of anti-
HBs (>1000 IU/l). Other HB serologic markers were
determined in the 1994 serum sample, which show that
he was not a chronically HB-infected patient (HBsAg
and HBeAg were negative) and that he had not been
infected with HBV before (anti-HBc and anti-HBe neg-
ative). Following the diagnosis of acute HBV infection
in 2007, we analysed a stored serum sample from
2004. No anti-HBsAg or anti-HBc antibodies were pres-
ent in this serum. To assess whether our patient was
infected with an aberrant HBV strain, we determined
the sequence of the surface protein encoding gene (S
gene), as previously described [11]. It turned out that
he was infected with a normal genotype A strain, which
is the most prevalent acute HBV strain in the Nether-
lands (Fig. 2). Immunologic testing after the acute phase
of the disease showed a normal number of lymphocytes
(2.34*109/l). However, the patient had a reverse
CD4:CD8 ratio with decreased T-cell responsiveness
against mitogens (data not shown), The patient did
not use immunosuppressive drugs at the time of HB vac-
cination or HBV infection, was not infected with HIV,
and had no apparent inherited immunodeﬁciencies.3. Discussion
To our knowledge, this report of an acute HBV infec-
tion in a male nurse working in a hospital is the ﬁrst
report of genuine HB vaccination failure [12,13] Despiteﬁve hepatitis B vaccinations our patient developed full-
blown acute HB within 15 years after receiving his last
vaccine. There are three plausible explanations for his
HB vaccination failure: (1) infection due to non-
response to the HB vaccine, (2) infection due to a vari-
ant HBV despite adequate immunity, and (3) infection
due to waning immunity:
1. Non-response or low response to HB vaccination is a
well-known phenomenon [2]. Our patient had
responded only marginally to his primary HB vacci-
nation series with plasma-derived vaccines. However,
after boosting with a recombinant DNA-based vac-
cine, he reached excellent anti-HBs titres (>1000 IU/
l; 2 independent samples). Thus, non-response to
HB vaccination can be excluded as a reason for vac-
cination failure.
2. HBV-immune-escape variants have been suggested as
a reason for HB vaccination failure when they were
ﬁrst discovered [14]. Later, it turned out that these
variants were mainly found in the context of passive
immunity (HB immunoglobulin) such as liver trans-
plant patients [15] and children born to HBV-infected
mothers [16]. Sporadically antigenic variants are also
found among chronically infected people [17] and
blood donors [18]. Genetic analysis of the HBV iso-
late revealed that our patient was infected with a nor-
mal genotype A strain, which is the most prevalent
strain among men who have sex with men (MSM)
in the Netherlands [11] and elsewhere [19,20]. Our
patient belongs to this HB-infection risk group; he
reported that he had (unsafe) sex with at least ﬁve dif-
ferent male partners in the 6 months prior to the acute
HBV infection. On the basis of the DNA analysis, we
can exclude vaccination failure due to an HBV strain
with an aberrant S protein.
3. Serum analysis after his last booster vaccination
showed an excellent antibody response (>1000 IU/l
anti-HBs). However, in a retrospective analysis of a
2004 serum sample, 11 years after his last HB vaccina-
tion, no anti-HBs was detectable. It is known that
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Fig. 2. Phylogenetic tree (neighbour-joining algorithm, 250 bootstraps) of acute hepatitis B virus (HBV) isolates from the Netherlands. All available
sequences of acute HBV strains of the last 6 months of 2004 as well as the HBV isolate of our patient (MSM vaccine failure) were analysed. The most
likely source of transmission is indicated for each strain (MSM = men who have sex with men; hetero = heterosexual contact; other = multiple routes, e.g.
dentist, hairdresser, etc.; unknown = no transmission data available). Prototype genotype A strains are indicated by their genbank accession number.
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However, decline of anti-HBs to low or undetectable
levels is not seen as a risk factor, as long as initial
post-vaccination levels of anti-HBs are greater than
10 IU/l. Our patient clearly fulﬁlled this criterion.
The anti-HBs titres of our patient not only declined
rapidly after HB vaccination, but seem also to have
declined rapidly after hisHBV infection. Sevenmonths
after the onset of clinical symptoms, his anti-HBs titre
was only 10.2 IU/l. Despite the rapid decline in vac-
cine-induced anti-HBs antibodies, our patient was able
to mount an adequate immune response as he cleared
his HBV infection in the normal time. The waning of
vaccine induced immunity is apparently responsible
for the inadequate protection against HBV exposure.
Sub-clinical, transient HBV infections (isolated anti-
HBc positive only) in vaccinated children [22–25] and
adults [26–28] have been described, and they are most
frequently associated with no or little response to HB
vaccination. Also, one clinically relevant HBV infection
has been reported in a long-term follow-up study of a
plasma-derived vaccine trial involving homosexual
men [29]. Hepatitis B vaccination failure may be more
common than previously thought, since other cases
may not have been recognized or may not have been
published due to incomplete data on vaccination of
infected individuals. Furthermore, due to the relatively
high frequency of primary vaccination failure among
adults, acute HBV after HB vaccination cannot be clas-
siﬁed as a genuine vaccine failure if the post-vaccination
anti-HBs level is unknown.
On the basis of this case report, we conclude that the
generally accepted correlation of long-term immunity
after an adequate vaccine response does not hold true
for every individual. Because HB vaccination started
in the 1980s, it has been more than 10 years since many
healthcare workers have received their last HB vaccina-
tion. If more cases of genuine HB vaccination failure
surface, revaccination of healthcare workers with poor
initial HB vaccination responses at long intervals (e.g.
10 years) might be considered to secure the prevention
of HBV transmission in the healthcare setting.
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